Drugs / BRII-179
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06650852 | Oct 2024 → Jul 2026 overdue | chronic hepatitis B virus infection | Brii Biosciences Limited | Recruiting | No outcome recorded |
| Phase 2 | NCT06491563 | Aug 2024 → Dec 2026 expected | chronic hepatitis B virus infection | Brii Biosciences Limited | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04749368 | Apr 2021 → Jul 2023 | chronic hepatitis B virus infection | Brii Biosciences Limited | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BRII-179 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04749368 ↗ |
| Known as | VBI-2601 | “BRII-179 (VBI-2601) will be administered by intramuscular injection” NCT04749368 ↗ |
| Modality | Vaccine | “virus-like particle-based therapeutic vaccine (BRII-179)” PMID 40043858 ↗ Mar 2025 |
| Route | Intramuscular | “BRII-179 (VBI-2601) will be administered by intramuscular injection” NCT04749368 ↗ |